The combination of atorvastatin and ethanol is not more hepatotoxic to rats than the administration of each drug alone

Animal studies and premarketing clinical trials have revealed hepatotoxicity of statins, primarily minor elevations in serum alanine aminotransferase levels. The combined chronic use of medicines and eventual ethanol abuse are common and may present a synergistic action regarding liver injury. Our objective was to study the effect of the chronic use of atorvastatin associated with acute ethanol administration on the liver in a rat model. One group of rats was treated daily for 5 days a week for 2 months with 0.8 mg/kg atorvastatin by gavage. At the end of the treatment the livers were perfused with 72 mM ethanol for 60 min. Control groups (at least 4 animals in each group) consisted of a group of 2-month-old male Wistar EPM-1 rats exposed to 10 percent ethanol (v/v) ad libitum replacing water for 2 months, followed by perfusion of the liver with 61 nM atorvastatin for 60 min, and a group of animals without chronic ethanol treatment whose livers were perfused with atorvastatin and/or ethanol. The combination of atorvastatin with ethanol did not increase the release of injury marker enzymes (alanine aminotransferase, aspartate aminotransferase, and lactic dehydrogenase) from the liver and no change in liver function markers (bromosulfophthalein clearance, and oxygen consumption) was observed. Our results suggest that the combination of atorvastatin with ethanol is not more hepatotoxic than the separate use of each substance.

Hepatotoxicidad de prajmalina: diagnóstico farmacocinético por bromosulftaleina / Prajmaline hepatotoxicity: pharmaco-kinetic diagnosis by brumosulfthaleine

Escasas publicaciones abordan el efecto del primer paso de la prajmalina (N-propil ajmalina bitartrato), por lo que surgieron interrogantes sobre una posible respuesta hepatotóxica. Mediante valoraciones farmacocinéticas modelo dependiente en las que se emplean bromosulftaleína (BSP) como una medida de la función excretora del hígado, se demuestra que la prajmalina en aplicación crónica, prvoca efectos hepatotóxicos sobre un modelo experimental animal. Los valores obtenidos de la constante de depuración (K) se correlacionan con otras mediciones realizadas por el mismo colectivo de otros trabajos: variación de la fracción albúmina índices transaminasa glutamicooxalacética/fosfolipasa A2 (GOT/FPA) y creatin-fosfoquinasa/fosfolipasa A2 (CPK/FPA); se definen períodos críticos de degeneración de la capacidad excretora